Echinacea, Unspecified

Summary

Echinacea, Unspecified (CHEMBL4297943) is a phase-3 clinical-stage unknown; indicated across 2 conditions including common cold and pharyngitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297943
Name	Echinacea, Unspecified
Type	Unknown
Max phase	3

Also known as: Coneflower, Echinacea, Echinacea juice, unspecified, ECHINACEA, UNSPECIFIED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
common cold	3	MONDO:0005709	EFO:0007214
pharyngitis	3	MONDO:0002258	MONDO:0002258

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	6
PHASE4	3
PHASE3	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00103012	PHASE4	COMPLETED	Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers
NCT01021995	PHASE4	COMPLETED	Echinacea Safety Study
NCT01046890	PHASE4	COMPLETED	Drug Interactions Between Echinacea Purpurea and Darunavir/Ritonavir
NCT00029211	PHASE3	COMPLETED	A Trial of Echinacea in Children
NCT00065715	PHASE3	COMPLETED	Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)
NCT00707902	PHASE3	COMPLETED	Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray Compared to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats
NCT07388615	PHASE2	RECRUITING	The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
NCT00032500	PHASE2	COMPLETED	Evaluation of Echinacea for the Common Cold
NCT00689468	Not specified	COMPLETED	Echinacea Purpurea and Osteopathy in Children With Recurrent Otitis Media
NCT00860795	Not specified	COMPLETED	Immunologic Effects of Echinacea
NCT01347658	Not specified	COMPLETED	Drug Interactions Between Echinacea Purpurea and Etravirine
NCT01396889	Not specified	COMPLETED	Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years
NCT05242718	Not specified	COMPLETED	Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants
NCT06583863	Not specified	COMPLETED	Parasitic Infections and Ulcerative Colitis: Combining Anti-parasitic and Immunomodulatory Treatments May Achieve Remission

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).